Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort
An erratum to this article was published (Lancet Diabetes Endocrinol, Mar 2025 ↗)
Authors' conclusion
The Primary Aldosteronism Medical Treatment Outcome (PAMO) criteria represent an internationally developed outcome standard that can guide clinical practice and research into primary aldosteronism. Efforts to optimise treatment intensity and minimise factors associated with an absent treatment response are needed to improve patient outcomes.
Study context
- Population
- Patients with PA who started targeted medical treatment between 2016 and 2021 at 28 centres; mean age 52 years (SD 11.5), 610 (48.5%) female31-expert Delphi panel
- Participants
- 1,258 patients
- Outcome
- Complete, partial or absent biochemical and clinical outcomes of medical treatment of PA (PAMO criteria)
- Follow-up
- 6-12 months post-treatment
Methodological detailsDelphi method, multicentre (28 centres)
- Delphi method
- Multicentre (28 centres)
Recommendations
As reported in the abstract
Treatment response (PAMO criteria) · 6-12 months
- Patients with biochemical outcome data
- 1057 (84.0%)
- Complete biochemical response
- 559 [52.9%]
- Patients with clinical outcome data
- 1248
- Complete clinical response
- 228 [18.3%]
- Absent clinical response
- 227 (18.2%)
Further findings
Median daily spironolactone dose, complete vs no complete biochemical response · higher with complete response
P = 0.011
Factors associated with complete vs partial or absent clinical response
| OR (95% CI) | P value | ||
|---|---|---|---|
| WomenMore likely complete response | 2.099 (1.485–2.968) | P < 0.001 | |
| Antihypertensive dose at baselineLower doses with complete response | 0.687 (0.603–0.782) | P < 0.001 | |
| Microalbuminuria or left ventricular hypertrophyLess likely with complete response | 0.584 (0.391–0.873) | P = 0.009 | |
| 0.20.5125Odds ratio (log scale) |
Original publication
Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort. Lancet Diabetes Endocrinol. Published 14 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →